The prevalence of transmitted resistance to antiretroviral drugs varies geographically, with little known about this effect in Asia. In Korea, zidovudine has been widely administered, without charge, through the National AIDS program since the early 1990s; with other potent antiretroviral agents also being introduced in the late 1990s. An analysis of the drug susceptibility to antiretroviral drugs was performed by genotyping of the drugresistant mutations in HIV on plasma samples from 50 HIV-infected patients who had received no treatment, between February 1998 and November 2002, which was interpreted according to the consensus guidelines of the International AIDS Society-USA panel. The median CD4 cell count was 100 cells/mm 3 ; the mean plasma RNA level was (5.19 6 0.56) log copies per milliliter. Of the 50 subjects tested 4 (8.0%) had one or more major drug-resistance mutation. The prevalence of resistance to multiple classes of drugs was 2.0%. No mutations, associated with resistance to nonnucleoside reverse transcriptase inhibitors, were identified. Resistant mutations of the reverse-transcriptase gene were found at codons 67, 70, 118, 215, and 219, and a resistant mutation of the protease gene was found only at codon 46 (2.6%, 1 of 39). There was an 8.0% prevalence of primary drug resistance to antiretroviral drugs in Korean patients infected with HIV-1. 1039 
INTRODUCTION H
IGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) has reduced HIV-related morbidity and mortality through effective viral suppression and immune recovery. [1] [2] [3] [4] However, incomplete viral suppression, from several causes, such as previous mono/dual therapy or low compliance, have brought out antiretroviral-resistant virus strains. The transmission of resistant HIV-1 to newly HIV-1-infected patients has also been demonstrated, [5] [6] [7] [8] [9] with increasing prevalence. 10 This is important in relation to therapeutic and public health aspects. 11 In Korea, zidovudine has been supplied by the government since 1990, without charge, through a nationwide AIDS program, which has resulted in easy access to long-term monotherapy for HIV-1 patients. In 1998, a protease inhibitor (PI), indinavir, was first introduced into practice. 12 HIV patient care has been limited to several centers due to the low prevalence and limited facilities. The history of HAART in Korea is short considering that PIs have been in active use for only 4 years. There are geographical differences in the primary antiretroviral resistance rates in drug-naive HIV patients, and particular situations, such as the Korean zidovudine program, may be contributing to the prevalence. We studied the antiretroviral resistance rate of drug-naive Korean HIV-1 patients, in relation to the background of easy-access long-term zidovudine therapy.
University Hospital, were enrolled. All were Korean Nationals. The eligible patients were all naive to any antiretroviral therapy, with plasma virus levels .3.0 log 10 copies/ml, as measured by the Amplicor assay with 400 copies/ml as the limit of detection (Roche Molecular Systems). The date of HIV infection was not estimated, and the medical records were reviewed retrospectively.
RNA extraction, cDNA synthesis, and PCR
Plasma samples were used to evaluate the HIV-1 reverse transcriptase (RT) and protease genotypes. Viral RNA was extracted with a High Pure RNA Isolation Kit (Roche, Mannheim, Germany) and was transcribed to cDNA using Superscript II (Gibco, USA), with NE1 as reverse primer (59-CCTACTA-ACTTCTGTATGTCAT TGACAGTCCAGCT-3 9). The reverse transcription was carried out in a final volume of 20 ml, containing 1 3 first strand buffer, 10 mM dithiothreitol, 0.5 mM deoxynucleoside triphosphate, 20 pmol of reverse primer, and 200 U of Superscript II, at 42°C for 60 min and 94°C for 5 min.
The protease and RT genes were amplified from cDNA by a nested PCR method using separate primer sets. The outer primers A (59-TTGGTTGCACTTTAAATTTTCCCATTAG-TCCTATT-39) and NE1, and the inner primers is (59-GGATG-GCCCAAGAGTTAAAC-3 9) and ias (59-CCATCCAAAG-GAATGGAGGT-39) were used for the RT genes. The outer primers p1 (59-CAGAGC CAACAGCCCCACCAG-3 9) and p2 (59-CTTTTGGGCCATCCATTCCTGGC-3 9), and the inner primers p3 (59-ACTGTATCCTTTAACTTCCC-3 9) and p4 (59-AGTTTCAATAGGACTAATGGG-3 9) were used for the protease genes. 13 The PCRs were carried out in a final volume of 50 ml. The reaction mixture consisted of 1 3 PCR buffer, 0.2 mM deoxynucleoside triphosphate, 50 pmol of each primer, and 1 U of ExTaq polymerase (TaKaRa, Japan). The PCR conditions for the RT genes were 94°C for 5 min, followed by 35 cycles at 94°C for 20 sec, 58°C for 30 sec, and 72°C for 30 sec, with a final extension step at 72°C for 5 min. The PCR conditions for the protease genes were 95°C for 5 min, followed by 35 cycles at 94°C for 15 sec, 58°C for 1 min, and 72°C for 2 min, with a final extension step at 72°C for 7 min (GeneAmp PCR system 2400, Perkin-Elmer, USA).
Sequencing reactions
The amplified fragments were purified with a QIAamp PCR purification kit (QIAGEN, USA). The sequencing reactions were performed in an MJ Research Gradient Cycler, using a Dye Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq DNA polymerase (FS enzyme) (Applied Biosystems), following the manufacturer's protocol. Single-pass sequencing was performed on each template using the stated primers. The fluorescent-labeled fragments were purified from the unincorporated terminators using an ethanol precipitation protocol. The samples were resuspended in distilled water and subjected to electrophoresis in an ABI 3700 sequencer (Applied Biosystems). All primary readings were edited to remove vector sequences and unreliable data using the Factura program (Perkin-Elmer). Sequences longer than 100 nucleotides were further analyzed.
Sequence and phylogenetic analysis
Consensus guidelines for the testing of resistance to antiretroviral drugs 14 were used to define well-characterized drugresistant mutations for the RT and protease inhibitors. The genetic subtype was determined by sequence analysis program (http://hivdb.stanford.edu/), and the phylogenetic tree constructed by the neighbor-joining method using the pol genes sequences.
Nucleotide sequence accession numbers
The protease and RT sequences are available in GenBank with the following accession numbers: AY242863 , AY242948.
RESULTS

Clinical profiles of the patients
Of the 50 patients studied, analysis of the reverse transcriptase gene was available in 47 and that of the protease gene in 39. The median age of subject patients was 40 years. The sexual orientations of the patients were heterosexual in 41 (82%) patients and bisexual in 9 (18%) patients. There was no intravenous drug use-related transmission, but 7 (14%) patients were assumed to be infected by sexual contacts with foreigners. The sequence analysis for the antiretroviral susceptibility genotyping was performed a median of 2 months after the HIV infection had been documented. The median CD4 cell count was 100 cells/mm 3 ; the mean plasma RNA level was 5.19 log copies/ml (Table 1) .
Genotypic drug resistance
Of the 50 subjects there were 4 (8.0%) with one or more major drug-resistant mutations. Three (6.4%) of the 47 subjects had nucleoside reverse transcriptase inhibitor (NRTI)-related genotypic mutations. No mutations associated with resistance to NRTIs were identified. The prevalence of resistance to multiple classes of drugs was 2.0%. Zidovudine-related resistant mutations were identified in 4.3% (2 of 47). Resistant mutations of the reverse-transcriptase gene were found at codons 67, 70, 118, 215, and 219, but resistant mutation of the protease gene was found only at codon 46, which was associated with the major resistance to indinavir (Table 2) .
Phylogenetic analysis
The sequence analysis showed no evidence of sample contamination. Of the 50 sequences, two were subtype A, one was subtype G, and all the others were subtype B.
DISCUSSION
Zidovudine monotherapy was performed from 1987 until 1994, when the dual therapy with RTIs began. The development of PIs in 1996 has made HAART possible, which has reduced HIV-related morbidity and mortality through effective virus control and immune recovery. However, several factors, such as the genetic diversity of HIV, mono/dual therapy, compliance, and pharmacokinetics of antiretroviral drugs, have contributed to the occurrence of drug-resistant HIV. HIV-infected patients continue their risky behavior, even after HIV has been diagnosed. The transmission of drug-resistant HIV through sexual contacts, perinatal infection, and the intravenous drug route has been demonstrated. [5] [6] [7] [8] [9] Although the worldwide prevalence of primary HIV resistance is increasing, there are geographical differences, for which there may be several contributing factors, such as differences in HIV prevalence, availability of potent antiretroviral drugs, and regional compliance to therapy. The primary HIV resistance in Asia is not well known.
As of December 2002, 2008 HIV patients were officially identified in Korea. Of these 97.5% were assumed to be infected through sexual contact, with 67.6% through heterosexual contacts. The current prevalence of HIV infection is relatively low, but the trend toward sexual liberalism and the high percentage of heterosexual infections imply a future increase in prevalence. For this reason there are concerns about primary HIV resistance. In Korea, zidovudine has been supplied since 1991, without charge. Although didanosine (May 1993) and lamivudine (October 1997) were introduced into practice thereafter, zidovudine monotherapy was the mainstream therapy, due to its easy accessibility, until the introduction of a PI, indinavir, in early 1998. Therefore, South 10 and 9-21% in Europe. [16] [17] [18] Although the period of our study was broader, the Korean prevalence is lower, with statistical significance (x 2 , p 5 0.03), than that reported by Little et al. 10 The low median CD4 cell count (100 cells/mm 3 ) of our patients implies that our data do not represent the initial primary resistance rate, and the actual primary resistance rate may be somewhat higher than the 8.0% found by ourselves. The zidovudine-related drug-resistant rate of HIV-1 in our study was 4.3%. A study reported an 8-11% drug resistance rate for zidovudine, between 1988 and 1994, in Switzerland and Australia, and 1.4 (1988-1991), 7.5 (1992), and 10.4% (1993) (1994) in North America. 19 In Spain, this figure was 12.8% (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) . 20 Even though our data might be an underestimation, the zidovudine-related drug resistance rate in Korea was much lower, regardless of the background of easy access to long-term zidovudine therapy. This means that regardless of the easy accessibility to zidovudine therapy, a limited number of HIV patients could afford to get antiretroviral therapy. The previous low prevalence, and less concern about treatment by patients, could be a possible explanation. The drug-resistant rate to PIs was 2.6% (1 of 39) in this study, with M46I being the major mutation related to the use of indinavir. This reflects the short history of PIs use in Korea, and the relatively longer use of indinavir in practice.
GENOTYPIC RESISTANCE IN DRUG-NAIVE HIV-1 PATIENTS IN KOREA 1041
There were no statistically significant differences in the prevalence of drug-resistant mutations among the CD4 cell count at drug-resistant testing, HIV RNA titer, and time elapsed from HIV diagnosis to drug-resistant testing (data not shown). All the patients with major drug-resistant mutations denied contact with foreigners and a history of overseas travel.
Since the first reported Korean case of HIV-infection, in 1985, 21 the number of HIV-infected patients has increased steadily. Although the absolute number of patients is small, the recent increase in HIV-infected patients has been marked. A recent study 12 showed that 52% of patients taking HAART had inadequate compliance. Previous long-term zidovudine monotherapy contributed little to the prevalence of drug-resistant HIV mutations, but the increasing number of newly infected patients, and the increased accessibility to HAART, require persistent surveillance for monitoring the frequency of drug-resistant HIV mutations.
In summary, there was an 8.0% prevalence of primary antiretroviral drug resistance found at a Korean tertiary university hospital, between February 1998 and November 2002.
